Single-Arm Trial of EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Head and Neck Carcinoma Metastatic/Refractory Nasopharyngeal Carcinoma
Latest Information Update: 27 Feb 2023
At a glance
- Drugs LMP2 specific TCR T cells-TCRCure Biotech (Primary)
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer
- Focus Adverse reactions
- 21 Feb 2023 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2023.
- 21 Feb 2023 Planned initiation date changed from 1 Sep 2020 to 1 Mar 2023.
- 21 Feb 2023 Status changed from not yet recruiting to recruiting.